Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Rhea-AI Summary

Tempest Therapeutics (TPST) collaborates with BIDMC to present preclinical data on TPST-1120 for renal cell carcinoma at AACR Annual Meeting.

BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classⁱ targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the Beth Israel Deaconess Medical Center (BIDMC) at Havard Medical School will present a poster with preclinical data supporting the advancement of TPST-1120 as a potential treatment for renal cell carcinoma (RCC) at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024 in San Diego, CA.

Poster presentation details:
Title:		PPAR-α Antagonist Enhances Immunotherapy and Anti
		Angiogenic Therapy to Inhibit Murine Renal Cancer
Abstract Number:		3045
Date & Time:		Monday, April 8, 2024; 1:30 – 5:00 p.m. PT
Session Title:		Oncogenic Transcription Factors
Location:		Poster Section 18

All regular abstracts are available for viewing via AACR’s online itinerary planner, located here.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor & Media Contacts

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

i If approved by the FDA

What is the focus of Tempest Therapeutics' collaboration with BIDMC?

The collaboration aims to present preclinical data on TPST-1120 for renal cell carcinoma.

Where will the poster presentation take place?

The poster presentation will be at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.

What is the title of the poster presentation?

The title is 'PPAR-α Antagonist Enhances Immunotherapy and Anti Angiogenic Therapy to Inhibit Murine Renal Cancer'.

When is the poster presentation scheduled?

The presentation is scheduled for Monday, April 8, 2024, from 1:30 – 5:00 p.m. PT.